Related Experiment Video
Updated: Sep 2, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination
Ya-Ting Liu1, Shang-Shang Wang1
1Department of Dermatology Huashan Hospital Fudan University Shanghai China.
Abstract:
Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause. We report a 67-year-old man with Pityriasis rubra pilaris might induced by COVID-19 vaccination. The patient developed the lesions after the first dose of vaccine and significantly aggravated after the second dose. He had poor effect and liver function impairment developed after acitretin used, but achieved satisfactory efficacy after replacement to ixekizumab, an interleukin-17A inhibitor.
Related Concept Videos
Myocarditis III: Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Myocarditis IV: Nursing Management
